Last reviewed · How we verify
NCT04156204
Immunosuppressant Medication Dosed Daily After Kidney Transplant
EARLY_PHASE1 trial testing Medication Event Monitoring System (MEMS) in Kidney Transplant Rejection in 1 participant. Terminated before completion.
27 November 2020
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 1 |
| Start date | 20 November 2019 |
| Primary completion | 27 November 2020 |
| Estimated completion | 27 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Medication Event Monitoring System (MEMS)
- Once-Daily Tacrolimus extended release — full drug profile →
Conditions studied
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
- Medication Adherence — all drugs for Medication Adherence →
Sponsor
University of Colorado, Denver
Who can join
Adults 13 to 22, any sex, with Kidney Transplant Rejection or Medication Adherence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Medication non-adherence is a major risk factor for graft dysfunction and graft loss among pediatric and adult transplant recipients. Rates of non-adherence in these populations are estimated between 30 and 70%, with the highest prevalence in adolescent and young adult (AYA) transplant recipients. Treatment-related factors known to impact rates of adherence include the number of medication doses per day and the number of tablets or capsules a patient takes per day, or "pill burden". One approach to minimizing dosing frequency and pill-burden includes transitioning patients to once-daily formulations. The current literature investigating utilization of once-daily immunosuppressive regimens in the AYA kidney transplant population is limited.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04156204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Medication Event Monitoring System (MEMS)
Trials testing the same drug.
- NCT02343159 — Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Mu · Phase 4 · terminated
Other recruiting trials for Kidney Transplant Rejection
Currently open trials in the same condition.
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06564649 — PROACT Pilot Trial · active not recruiting
- NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
- NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04156204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 2 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing